NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.



NUCALA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.

  • NUCALA is not indicated for treatment of other eosinophilic conditions.
  • NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.  

   818521R0 April 2017